SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

United Therapeutics Corporation UTHR announced that the FDA has approved the new drug application for the dry powder inhalation (DPI) formulation for its key pulmonary arterial hypertension (PAH) drug ...

Shares of United Therapeutics UTHR rose 15% on Apr 1, following FDA approval for label expansion of its pulmonary arterial hypertension (PAH) drug, Tyvaso. Tyvaso Inhalation Solution is now approved ...

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 The pivotal TETON-1 phase 3 study of nebulized Tyvaso® ...

China's factory activity stalled in May as new export orders contracted and input costs kept rising, an official survey showed on Sunday, ‌adding to concerns the world's second-largest economy is ...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® ...

United Therapeutics UTHR announced that FDA has accepted and granted priority review to its a new drug application (NDA) seeking approval of its drug device combination therapy, Tyvaso dry powder ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Interstitial lung disease (ILD) refers to a group of conditions that cause damage and stiffness in the lung tissue. Over time, this damage can make it harder for oxygen to move into the bloodstream.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...